Neratinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Neratinib
Neratinib: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Neratinib, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The four known uses below are in the same disease category as an approved indication (breast cancer).
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 4 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| progesterone-receptor positive breast cancer | breast cancer |
| normal breast-like subtype of breast carcinoma | breast cancer |
| progesterone-receptor negative breast cancer | breast cancer |
| breast tumor luminal A or B | breast cancer |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02490536 | NERLYNX | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (irreversible pan-HER tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert; the literature highlights gastrointestinal tolerability as a key concern |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction query returned 100 records; the first 20 reviewed include many Major-level interactions, notably with:
- Acid-reducing agents: famotidine, ranitidine, cimetidine, and proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole)
- Aprepitant
- Dexamethasone
- Clarithromycin
- Clotrimazole
- Moderate interactions include loperamide, antacids (magnesium oxide, aluminum hydroxide, calcium carbonate), empagliflozin and naldemedine.
- Literature notes that significant gastrointestinal side effects often lead to treatment discontinuation (PMID 39153126).
Please refer to the package insert for warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.